Science Comedy, Shifting Rules For Abortion Pills. Jan 6, 2023, Part 1

Science Comedy, Shifting Rules For Abortion P...

Up next

Telling the tale of human origins, one fossil tooth at a time

Where did we come from? How did humanity, with our complicated civilizations and all our human quirks and foibles, come to be? Much of what we know about those questions traces back to important fossil finds in Ethiopia. Paleoanthropologist Yohannes Haile-Selassie has been key in ...  Show more

Did the fire at the Library of Alexandria set humanity back?

In 48 B.C.E., a massive fire ripped through the Library of Alexandria in Egypt, one of the largest and most significant ancient libraries. An estimated 100,000 works of literature were lost. Throughout history, there are lots of examples of things being “lost”: cities, like Pompe ...  Show more

Recommended Episodes

Abortion Pills, Take Two
Radiolab

Abortion pills — a combo of two drugs, mifepristone and misoprostol — are on notice: on April 7, 2023, a federal judge said the FDA’s approval of mifepristone was invalid. And then, not more than an hour later, another federal judge in a separate case said that mifepristone ha ...

  Show more

A Little Bit Pregnant
Invisibilia

This week on Invisibilia, could the rebrand of a familiar pill open up a new way to control fertility in a post-Roe America?See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Pri ...  Show more

Mail-Order Pharmacy Dispensing of Mifepristone for Abortion After In-Person Screening
JAMA Internal Medicine Author Interviews

Interview with Daniel Grossman, MD, author of Mail-Order Pharmacy Dispensing of Mifepristone for Medication Abortion After In-Person Screening, and Emily M. Godfrey, MD, MPH, author of Primary Care's Role in Prescribing Mail-Order Mifepristone. Hosted by Eve Rittenberg, MD. Relat ...  Show more

The Abortion Pill Legal Standoff Endangers Access to All Drugs
Science, Spoken

A Fifth Circuit ruling that keeps mifepristone available, but curtails access to it, is the newest front in a battle over the FDA’s power to approve medications. Read the story here. Learn more about your ad choices. Visit podcastchoices.com/adchoices